Home Newsfeeds Benchmark Reiterates Buy on Harvard Bioscience, Maintains $4 Price Target

Benchmark Reiterates Buy on Harvard Bioscience, Maintains $4 Price Target

Benchmark analyst Kenneth Bruce reiterates Harvard Bioscience (NASDAQ:HBIO) with a Buy and maintains $4 price target.

byBenzinga Newsdesk

March 10, 2023

1 minute read

Benchmark analyst Kenneth Bruce reiterates Harvard Bioscience (NASDAQ:HBIO) with a Buy and maintains $4 price target.

Mitsubishi Plans To Invest Up To €200M In Renault’s EV Unit Ampere

By Nabaparna Bhattacharya

October 24, 8:43 AM

Japan's Mitsubishi Motors (OTC: MMTOF) plans to invest in Ampere,

MMTOF

Where Are Psychedelics Headed In 2023? These Two Heavy Hitters Share Their Plans

By Lara Goldstein

January 9, 10:26 PM

It’s the beginning of 2023 and psychedelics companies are updating the public on their developmental and clinical progress as well as their selected milestones for the year.

CYBN

Oppenheimer Maintains Outperform on Citigroup, Raises Price Target to $87

By Benzinga Newsdesk

February 2, 9:44 AM

Oppenheimer analyst Chris Kotowski maintains Citigroup (NYSE:C) with a Outperform and raises the price target from $83 to $87.

Johnson & Johnson Asbestos Claims Continue: California Man Alleges Baby Powder Led to Rare Cancer

By Vandana Singh

July 11, 8:31 AM

A California man, Emory Hernandez Valadez, claims he developed a rare form of cancer due to exposure to asbestos in Johnson & Johnson's (NYSE: JNJ) talc-based baby powder.

JNJ

Benchmark Reiterates Buy on Harvard Bioscience, Maintains $4 Price Target

Related Posts

Mitsubishi Plans To Invest Up To €200M In Renault’s EV Unit Ampere

Where Are Psychedelics Headed In 2023? These Two Heavy Hitters Share Their Plans

Oppenheimer Maintains Outperform on Citigroup, Raises Price Target to $87

Johnson & Johnson Asbestos Claims Continue: California Man Alleges Baby Powder Led to Rare Cancer